§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US6358989B1 Expired / Lapsed US ⏱️ 0.0 years remaining

Therapeutic inhibitor of vascular smooth muscle cells

Assignee: UAB Research Foundation
•
Filing: 1999-07-26
•
Granted: 2002-03-19
•
Expires: 2019-07-26
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Inventors

  • 👤 Lawrence L. Kunz
  • 👤 Richard A. Klein
  • 👤 John M. Reno

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 15:35
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/04; A61K31/13; A61K31/131; A61K31/135; A61K31/138; A61K31/16; A61K31/165; A61K31/17; A61K31/33; A61K31/335; A61K31/337; A61K31/365; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K31/495; A61K31/505; A61K31/519; A61K31/55; A61K31/551; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/6849; A61K47/69; A61K47/6921; A61K47/6923; A61K47/6927; A61L; A61L31/00; A61L31/08; A61L31/14; A61L31/148; A61L31/16; A61P; A61P43/00; A61P7/00; A61P9/00; A61P9/10; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/432; A61L2300/60; A61L2300/602; A61L2300/606; A61L2300/62; A61L2300/622; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323; Y; Y10; Y10S; Y10S977/00; Y10S977/902; Y10S977/904; Y10S977/906; Y10S977/915; Y10S977/92

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 50 words
A pharmaceutical composition suitable for delivery via an implantable device, comprising: (a) an amount of a cytochalasin or an analog thereof effective to inhibit or reduce stenosis or restenosis of a mammalian blood vessel traumatized by a surgical procedure; and (b) a pharmaceutically acceptable non-liquid release matrix for said cytochalasin.
Claim 2
Dependent Claim 50 words
A pharmaceutical composition suitable for delivery via an implantable device, comprising: (a) an amount of a cytochalasin or an analog thereof effective to inhibit or reduce stenosis or restenosis of a mammalian blood vessel traumatized by a surgical procedure; and (b) a pharmaceutically acceptable non-liquid release matrix for said cytochalasin.
Claim 3
Dependent Claim 13 words
The composition of claim 1 wherein the composition is coated on the device.
Claim 4
Dependent Claim 16 words
The composition of claim 1 wherein the release matrix comprises a gel, permeable membrane or paste.
Claim 5
Dependent Claim 19 words
The composition of claim 1 wherein the release matrix comprises microparticles or nanoparticles comprising the cytochalasin or analog thereof.
Claim 6
Dependent Claim 11 words
The composition of claim 1 wherein the cytochalasin comprises cytochalasin B.
Claim 7
Dependent Claim 11 words
The composition of claim 1 wherein the cytochalasin comprises cytochalasin D.
Claim 8
Dependent Claim 11 words
The composition of claim 1 wherein the cytochalasin comprises cytochalasin A.
Claim 9
Dependent Claim 14 words
The composition of claim 1 wherein the cytochalasin is an analog of cytochalasin B.
Claim 10
Dependent Claim 11 words
The composition of claim 1 which is contained in a mesh.
Claim 11
Dependent Claim 11 words
The composition of claim 1 wherein the device is a shunt.
Claim 12
Dependent Claim 11 words
The composition of claim 1 wherein the device is a stent.
Claim 13
Dependent Claim 12 words
The composition of claim 1 wherein the device is an artificial graft.
Claim 14
Dependent Claim 12 words
The composition of claim 1 wherein the device is an adventitial wrap.
Claim 15
Dependent Claim 24 words
A therapeutic shunt comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic shunt.
Claim 16
Dependent Claim 24 words
A therapeutic shunt comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic shunt.
Claim 17
Dependent Claim 17 words
The therapeutic shunt of claim 14 wherein the cytoskeletal inhibitor comprises a cytochalasin, or an analog thereof.
Claim 18
Dependent Claim 25 words
A therapeutic adventitial wrap comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic wrap.
Claim 19
Dependent Claim 25 words
A therapeutic adventitial wrap comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic wrap.
Claim 20
Dependent Claim 18 words
The therapeutic adventitial wrap of claim 16 wherein the cytoskeletal inhibitor comprises a cytochalasin, or an analog thereof.
Claim 21
Dependent Claim 28 words
A therapeutic artificial graft comprising an amount of a cytochalasin or an analog thereof effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic graft.
Claim 22
Dependent Claim 28 words
A therapeutic artificial graft comprising an amount of a cytochalasin or an analog thereof effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic graft.
Claim 23
Dependent Claim 35 words
A therapeutic device comprising a stent overlayed with an artificial graft, wherein the graft comprises an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic device.
Claim 24
Dependent Claim 35 words
A therapeutic device comprising a stent overlayed with an artificial graft, wherein the graft comprises an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis following placement of the therapeutic device.
Claim 25
Dependent Claim 17 words
The therapeutic device of claim 19 wherein the cytoskeletal inhibitor comprises a cytochalasin, or an analog thereof.

References Cited (Backward Citations)

US4070484A Cited
USRE32944E Cited
US3940422A Cited
US4093709A Cited
US4235988A Cited
US4732763A Cited
US5324736A Cited
US5098903A Cited
US4442119A Cited
US4389330A Cited
US5332584A Cited
US4675189A Cited
US5047431A Cited
US4485096A Cited
US4879315A Cited
US5015666A Cited
US4485097A Cited
USRE33403E Cited
US4577636A Cited
US4512762A Cited
US4555402A Cited
US4840939A Cited
US4867973A Cited
US5226430A Cited
US4897255A Cited
US5284763A Cited
US4824436A Cited
US4826672A Cited
US4744981A Cited
US4906452A Cited
US5316766A Cited
US4935415A Cited
US4859585A Cited
US4962091A Cited
US4879225A Cited
US5314679A Cited
US4839155A Cited
EP0260066B1 Cited
US5120535A Cited
US4994384A Cited
US4959355A Cited
US4968350A Cited
US5114719A Cited
US5093330A Cited
EP0297946A2 Cited
US5527337A Cited
US4835002A Cited
US5216024A Cited
US5221620A Cited
US4929602A Cited
US4997652A Cited
US4973601A Cited
US5232444A Cited
US5468746A Cited
US5167960A Cited
US5213580A Cited
US5066789A Cited
US5208019A Cited
EP0365863B1 Cited
US5340925A Cited
US5268358A Cited
US5032679A Cited
US5380716A Cited
US5304541A Cited
EP0374044B1 Cited
EP0451202B1 Cited
US5073633A Cited
US5015578A Cited
US5356713A Cited
US5364632A Cited
US5026537A Cited
US5288735A Cited
US5407609A Cited
US4994033A Cited
US5248764A Cited
US5208238A Cited
US5395610A Cited
US5346897A Cited
US5364843A Cited
US5242397A Cited
US5112305A Cited
US5043335A Cited
EP0411893A3 Cited
US4990538A Cited
US5009659A Cited
US5059166A Cited
US5176617A Cited
US5232911A Cited
US5049132A Cited
US5199939B1 Cited
US5199939A Cited
US5328471A Cited
US5260224A Cited
US5140012A Cited
US5166143A Cited
US5282785A Cited
US5189046A Cited
US5189212A Cited
US5192525A Cited
US5219548A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2005-03-18 2005-09-17 2006-03-19 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2009-03-18 2009-09-17 2010-03-19 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2013-03-18 2013-09-17 2014-03-19 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag